Monday, October 5, 2026

AI Hardware Supply Chain Expands as Chip Makers Race to Meet Training Infrastructure Demand

The AI hardware infrastructure market is experiencing a buildout across semiconductors, memory, and data center connectivity as companies scale capacity to support growing AI workloads. With the AI processor market projected to grow from $43.7B to over $323B, suppliers including Credo Technology and Aehr Test Systems are reporting bullish forecasts while Google's custom silicon strategy challenges Nvidia's dominance.

AI Hardware Supply Chain Expands as Chip Makers Race to Meet Training Infrastructure Demand
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

The infrastructure backbone supporting next-generation AI systems is undergoing rapid expansion as semiconductor manufacturers, testing equipment providers, and connectivity specialists scramble to meet surging demand from hyperscalers and enterprise AI deployments.

The AI processor market is projected to surge from $43.7 billion to over $323 billion, driving sustained investment across multiple layers of the hardware stack—from advanced semiconductors and high-bandwidth memory to data center connectivity and edge computing capabilities. This growth trajectory is fueling aggressive capacity expansion and optimistic forward guidance from key infrastructure players.

Credo Technology Group, a provider of high-speed connectivity solutions for AI data centers, is projecting GAAP gross margins between 63.8% and 65.8% for Q3 FY2026, signaling strong pricing power in the connectivity layer that links AI accelerators. The company's margins reflect the premium economics of specialized infrastructure components as data centers race to eliminate bottlenecks in chip-to-chip and rack-to-rack communication.

Meanwhile, Aehr Test Systems, which supplies burn-in and test equipment for AI chips, reported receiving "very large forecasts" from its lead Sonoma production customer, with shipments expected to commence in Q1 FY2027. The company is forecasting $60 million to $80 million in bookings for the second half of FY2026, primarily driven by AI wafer-level and packaged-part burn-in systems. Aehr's CEO indicated the company has capacity exceeding 20 systems per month for both wafer-level and package-level testing—a critical capability as AI chip complexity increases.

The company's Silicon Valley test lab has received multiple orders for new high-power Sonoma configurations capable of handling up to 2,000 watts per device, reflecting the escalating power requirements of cutting-edge AI accelerators. Aehr has also expanded its partnership with ISE Labs and ASE, the world's leading outsourced semiconductor assembly and test platform, to provide wafer-level and packaged-part testing services for top-tier semiconductor customers in HPC and AI applications.

The competitive landscape is shifting as Google's custom silicon strategy matures, presenting targeted challenges to Nvidia's market dominance. Hyperscalers are increasingly investing in proprietary accelerator designs optimized for their specific AI workloads, fragmenting what was once a more concentrated market.

Industry analysts point to the "memory wall"—the bandwidth bottleneck between processors and memory—and advanced packaging technology as the next critical competitive frontiers. High-bandwidth memory (HBM) supply constraints and 3D packaging capabilities are emerging as key differentiators in the race to deliver performance improvements for large language models and other compute-intensive AI applications.

The sustained infrastructure investment reflects not just current AI deployment needs but anticipated growth in inference workloads as AI models move from training to production deployment at scale. As enterprises increasingly adopt AI capabilities, the demand for specialized compute, storage, and networking infrastructure is expected to intensify throughout the remainder of the decade.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score7 source documents7 with a live linkVerifiability: High
  1. [1]Earnings callNasdaq· January 16, 2026
    Aehr Test (AEHR) Q2 2026 Earnings Call Transcript
  2. [2]News articleYahoo Finance· December 1, 2025
    Credo Technology Group Holding Ltd Reports Second Quarter of Fiscal Year 2026 Financial Results
  3. [3]News articleYahoo Finance· February 10, 2026
    Einride to Appoint Former NVIDIA Executive Gary Hicok to Board of Directors
  4. [4]Press releaseGlobeNewswire· November 6, 2025
    Ensurge Micropower ASA – Contemplated private placement
  5. [5]News articleYahoo Finance· December 5, 2025
    Stock market today: S&P 500, Nasdaq, Dow rise as Fed-favored PCE inflation data cools
  6. [6]News articleYahoo Finance· February 17, 2026
    Stock market today: Dow, S&P 500, Nasdaq end higher in volatile trading day as Apple jumps
  7. [7]Press releaseGlobeNewswire· December 11, 2025
    Wafer Dicing Services Market Set to Exceed US$ 932.9 Million by 2035 | Astute Analytica

In this story

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com